FOLH1 and Familial prostate cancer: To assess antigen-specific killing, CAR T cells were co-cultured with PSMA-positive (C4-2, LNCaP, PC3-PSMA) and PSMA-negative (DU145) prostate cancer cell lines across a range of effector-to-target ratios (E:T; 1:1 to 1:64).